6 results on '"Dawei Tian"'
Search Results
2. AB175. Girdin protein is a novel prognosis predictor for patients with non-muscle invasive bladder cancer
- Author
-
Wenlu Zhao, Bo Zhang, Hailong Hu, Changli Wu, Zhouliang Zhouliang Wu, Yu Zhang, and Dawei Tian
- Subjects
Bladder cancer ,business.industry ,Urology ,urologic and male genital diseases ,medicine.disease ,recurrence and progression ,Printed Abstracts ,Text mining ,Reproductive Medicine ,Cancer research ,Carcinoma ,Medicine ,bladder cancer ,business ,Non muscle invasive ,Girdin ,non-muscle invasive bladder cancer (NMIBC) - Abstract
Objective This study aimed to determine the expression status of actin-binding protein Girdin in non-muscle invasive bladder cancer (NMIBC) tissues, and to explore the relationships between Girdin expression and the clinicopathological characteristics of bladder carcinoma. Methods This study included 160 patients with NMIBC who underwent surgery from January 2006 to January 2011 at Second Hospital of Tianjin Medical University. The correlations between Girdin expression and the clinicopathological parameters were examined by Chi-square test. Recurrence-free survival (RFS) and progression-free survival (PFS) were analyzed using Kaplan-Meier method. The prognostic significance of Girdin expression was assessed using univariate and multivariate Cox regression analysis models. Results Girdin positivity was more frequently seen in high-grade tumors than in low-grade tumors (P=0.019), and in undifferentiated tumors than in differentiated tumors (P=0.028). In Kaplan-Meier analysis, expression of Girdin was significantly associated with lower RFS (P=0.007) and PFS (P=0.024) rates. The univariate analysis revealed that Girdin expression was a risk factor for both recurrence and progression of NMIBC. Further multivariate analysis identified Girdin as an independent predictor of tumor recurrence [hazard ratio (HR) 2.056, 95% CI, 1.213–3.483, P=0.007]. Conclusions The present study suggests that Girdin is differentially expressed in bladder tumors and may represent an independent predictor of prognosis for patients with NMIBC.
- Published
- 2016
3. AB112. Expression of brain-specific angiogenesis inhibitor 1 and association with p53, microvessel density and vascular endothelial growth factor in the tissue of human bladder transitional cell carcinoma
- Author
-
Hailong Hu, Changli Wu, and Dawei Tian
- Subjects
bladder urothelial carcinoma ,Urology ,Human bladder ,Cancer ,Biology ,medicine.disease ,Tumor endothelial cell ,bladder epithelial cells ,Angiogenesis inhibitor ,Vascular endothelial growth factor ,chemistry.chemical_compound ,Transitional cell carcinoma ,Reproductive Medicine ,chemistry ,Immunology ,Poster Presentation ,Cancer research ,medicine ,Brain-specific angiogenesis inhibitor 1 (BAI1) ,Brain-Specific Angiogenesis Inhibitor 1 ,vascular endothelium ,Microvessel density - Abstract
Objective Brain-specific angiogenesis inhibitor 1 (BAI1) was initially described in 1997, and there have since been a number of studies on its expression in different types of cancer. The aim of the present study was to investigate the expression levels of BAI1 in bladder transitional cell carcinoma (BTCC) at different stages and the mechanism by which it inhibits tumor endothelial cell proliferation. Methods Normal bladder mucosa biopsy specimens were obtained as the control group, and human BTCC biopsy specimens were used as the study group. Immunohistochemical assays were used to detect the expression levels of BAI1, vascular endothelial growth factor (VEGF) and mutant p53, in addition to microvessel density (MVD) in the tissues. Western blotting was used to analyze the differential expression of BAI1 in the two samples. Results Statistical analysis was performed, which indicated that BAI1 expression levels in the normal bladder mucosa group were significantly higher than those in the BTCC group and were associated with clinical staging. BAI1 levels in the T1 stage BTCC tissues were higher than those in the T2–4 stage BTCC tissues (P
- Published
- 2016
4. B058. Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study
- Author
-
Dawei Tian, Hailong Hu, Changli Wu, and Yu Zhang
- Subjects
medicine.medical_specialty ,recurrence ,Bladder Urothelial Carcinoma ,Bladder cancer ,intravenous chemotherapy ,business.industry ,Bladder ,Urology ,Retrospective cohort study ,Intravenous chemotherapy ,urologic and male genital diseases ,medicine.disease ,Resection ,Reproductive Medicine ,Poster Presentation ,medicine ,Bladder tumor ,progression ,Stage (cooking) ,business ,Intravesical chemotherapy - Abstract
Objective The management of stage 1 and grade 3 (T1G3) bladder cancer continues to be controversial. Although the transurethral resection of bladder tumor (TURBT) followed by intravesical chemotherapy is a conservative strategy for treatment of T1G3 bladder cancer, a relatively high risk of tumor recurrence and progression remains regarding the therapy. This study aimed to compare the efficacy of intravenous chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone for T1G3 bladder cancer after TURBT surgery. Methods We retrospectively reviewed the cases of 457 patients who were newly diagnosed with T1G3 bladder urothelial carcinoma between January 2009 and March 2014. After TURBT, 281 patients received intravesical chemotherapy alone, whereas 176 patients underwent intravesical chemotherapy in combination with intravenous chemotherapy. Tumor recurrence and progression were monitored periodically by urine cytology and cystoscopy in follow-up. Recurrence-free survival and progression-free survival of the two chemotherapy strategies following TURBT were analyzed. Univariable and multivariable Cox hazards analyses were performed to predict the prognostic factors for tumor recurrence and progression. Results The tumor recurrence rate was 36.7% for patients who received intravesical chemotherapy alone after TURBT, compared with 19.9% for patients who received intravenous chemotherapy combined with intravesical chemotherapy after TURBT (P
- Published
- 2016
- Full Text
- View/download PDF
5. AB265. Association between MDM2 SNP309T>G polymorphism and the risk of bladder cancer: new data in Chinese population and an update meta-analysis
- Author
-
Linguo Xie, Hailong Hu, Tao Chen, Dawei Tian, and Changli Wu
- Subjects
Chinese population ,Bladder cancer ,biology ,business.industry ,Urology ,Mdm2 snp309 ,P53 Tumor Suppressor ,medicine.disease ,Bioinformatics ,Negative regulator ,Printed Abstracts ,mate-analysis ,enzymes and coenzymes (carbohydrates) ,MDM2 ,Reproductive Medicine ,rs2279744 ,Meta-analysis ,biology.protein ,Medicine ,Mdm2 ,business ,neoplasms - Abstract
Background MDM2 is a mainly negative regulator of p53 tumor suppressor pathway. We aimed to investigate evaluate the association between MDM2 SNP309 polymorphism and bladder cancer risk. Methods A total of 535 bladder cancer patients and 649 health controls were recruited for our study. MDM2 SNP309 T>G polymorphism was genotyped by PCR-LDR method. Logistic regression was used to analyze the relationship between the genotype and susceptibility of bladder cancer. Kaplan-Meier estimates and log rank test were obtained to analyze the association between the genotype and risk of recrudesce in NMIBC patients. A multivariable Cox proportional hazards model was fitted to identify independent prognostic factors. To further investigate the association, we conducted a meta-analysis including six studies. Results The frequency of the MDM2 SNP309 T>G polymorphism showed no significant difference between cases and controls (all P>0.05). In the stratification analysis, the results showed that G allele carriers were prone to have a significant decrease in risk of low-grade bladder cancer (adjusted OR: 0.613, 95% CI: 0.427–0.881), and G-variant was associated with a significant reduced risk of recurrence in NMIBC patients with or without chemotherapy (PG polymorphism has no influence on bladder cancer risk in Asians, but this SNP may be associated with genetic susceptibility of bladder cancer among Caucasians.
- Published
- 2016
- Full Text
- View/download PDF
6. AB111. Genetic variations rs11892031 and rs401681 are associated with bladder cancer risk in a Chinese population
- Author
-
Hailong Hu, Dawei Tian, Yu Zhang, and Changli Wu
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Urology ,Genome-wide association study ,Single-nucleotide polymorphism ,polymorphism ,03 medical and health sciences ,0302 clinical medicine ,Polymorphism (computer science) ,Internal medicine ,Genotype ,genome-wide association studies (GWAS) ,medicine ,Genetic association ,Bladder cancer ,business.industry ,Odds ratio ,medicine.disease ,Confidence interval ,030104 developmental biology ,Reproductive Medicine ,030220 oncology & carcinogenesis ,Poster Presentation ,genetic variations ,business - Abstract
Objective Genome-wide association studies (GWAS) have identified a number of genetic variants associated with risk of bladder cancer in populations of European descent. Methods we assessed association of two of these variants, rs11892031 (2q37.1 region) and rs401681 (5p15.33 region) in a Chinese case-control study, which included 367 bladder cancer cases and 420 controls. Results We found that the AC genotype of rs11892031 was associated with remarkably decreased risk of bladder cancer [adjusted odds ratio (OR), 0.27; 95% confidence interval (CI), 0.09–0.81; P=0.019), compared with the AA genotype of rs11892031; and that CT/CC genotypes of rs401681 were associated with significantly increased risk of bladder cancer (adjusted OR, 1.79; 95% CI, 1.10–2.91; P=0.02), compared with the TT genotype of rs401681. We further conducted stratification analysis to examine the correlation between single nucleotide polymorphism (SNP) rs11892031/rs401681 and tumor grade/stage. Results showed that heterogeneity in ORs of tumor categories was not significant for either rs11892031 or rs401681 (P>0.05), indicating that the two SNPs seemingly do not associate with tumor grade and stage of bladder cancer in our study population. Conclusions The present study suggests that the SNPs rs11892031 and rs401681 are associated with bladder cancer risk in a Chinese population.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.